Sentinel Lymph Node Biopsy in Melanoma: Indications, Technique, and Prognostic Significance

Clinical Overview

Sentinel lymph node (SLN) biopsy is a minimally invasive surgical staging procedure for melanoma patients that accurately detects regional lymph node metastases and stratifies patients into accurate prognostic groups. SLN biopsy involves: (1) injection of radioactive tracer and/or blue dye near the primary melanoma, (2) identification of lymph nodes that first receive lymphatic drainage from the primary site (sentinel nodes), and (3) removal and histopathologic examination of these nodes. SLN biopsy is the most sensitive method for detecting occult regional nodal metastases, identifying lymph node involvement in 25-30% of clinically node-negative melanoma patients with Breslow thickness 0.8-4mm. Detection of SLN positivity changes staging from Stage I-II to Stage III, substantially altering prognosis and treatment recommendations. SLN biopsy is now standard of care for intermediate-thickness melanoma (Breslow 0.8-4mm) because it provides accurate staging information that guides adjuvant therapy decisions. The procedure has low morbidity and can be performed with minimal operative time and recovery.

Epidemiology & Risk Factors

The risk of SLN positivity varies with Breslow depth: approximately 5% for Breslow 0.8-1.0mm, 15-20% for Breslow 1.01-2.0mm, 30-40% for Breslow 2.01-4.0mm, and 40-50% for Breslow >4.0mm. Other factors increasing SLN positivity risk include: ulceration (increases risk by ~10%), mitotic rate ≥1/mm² (increases risk), male sex, and older age. However, Breslow depth is the single most important predictor of SLN positivity. The prognostic significance of SLN biopsy is demonstrated by the AJCC TNM staging system: SLN-positive patients with same Breslow depth have substantially worse prognosis than SLN-negative patients (e.g., Stage IIIA melanoma with occult SLN micrometastasis has 5-year survival of 60-75%, while Stage IIA with negative SLN has 5-year survival of 80-85%).

Pathophysiology

Sentinel node biopsy is based on principles of lymphatic drainage: melanoma cells metastasize preferentially through lymphatic vessels to regional lymph nodes. The sentinel node is the first lymph node(s) to receive lymphatic drainage from the primary site. By identifying and examining the sentinel node(s), occult metastatic disease can be detected before it progresses to multiple node involvement or clinically detectable disease. Micrometastases (metastatic tumor deposits <2mm diameter) are detected in 25-30% of SLN biopsies in intermediate-thickness melanoma. These micrometastases indicate Stage III disease (upstaging from Stage II) and substantially alter prognosis and treatment (adjuvant immunotherapy is now recommended for SLN-positive patients to improve recurrence-free survival by 25-30%). The sensitive detection of SLN micrometastases by serial sectioning, immunohistochemistry (S100, Melan-A/MART-1, HMB-45), and molecular methods (RT-PCR for MART-1 mRNA) allows identification of occult disease that standard hematoxylin-eosin examination might miss.

Clinical Presentation & Classification

SLN biopsy is performed as elective staging procedure for patients with intermediate-thickness melanoma (Breslow 0.8-4mm) and clinically node-negative regional nodes. The procedure is typically performed at the time of wide local excision of the primary melanoma, though it can be performed separately if wide excision was already done. SLN mapping involves: (1) Lymphoscintigraphy: radioactive technetium-99m sulfur colloid is injected around the primary site 6-24 hours before surgery, followed by nuclear imaging to identify draining lymph node basins; (2) Intraoperative mapping: blue dye (1-2% isosulfan blue or methylene blue) is injected around the primary site in the operating room, with identification of blue-stained lymphatic vessels leading to sentinel nodes; (3) Gamma probe: radioactivity is detected using handheld gamma probe to identify sentinel nodes containing radioactivity. Patients receive sentinel node excision through small incision(s) in the appropriate lymph node basin(s) (typically inguinal, axillary, or cervical depending on melanoma location).

Diagnosis & Staging

Sentinel nodes are examined histopathologically with particular care: (1) Serial sections of the entire lymph node are prepared (thin 40-50 micrometer sections cut throughout the node), (2) hematoxylin-eosin staining is performed on multiple sections, (3) immunohistochemistry with melanoma-specific antibodies (S100, Melan-A/MART-1, HMB-45, SOX10) is performed on select sections to increase detection of small micrometastases, and (4) reverse transcription-polymerase chain reaction (RT-PCR) for MART-1 mRNA may be performed as additional molecular testing. SLN positivity ranges from: isolated tumor cells (few cells, <0.1mm), micrometastases (0.1-2mm deposits), and macrometastases (>2mm deposits). TNM staging incorporates SLN status: N1a indicates clinically occult SLN micrometastases (detected only on biopsy), which is less advanced than N1b (clinically evident SLN macrometastases). SLN positivity upstages patients from Stage I-II to Stage III, substantially altering prognosis and treatment decisions.

Treatment Algorithm

SLN-negative patients (Breslow 0.8-4mm, clinically node-negative regional nodes) typically undergo observation without completion lymph node dissection or adjuvant therapy, though adjuvant immunotherapy (pembrolizumab or ipilimumab) may be discussed for Stage IIC patients. SLN-positive patients undergo: (1) Completion lymph node dissection: removal of all lymph nodes in the involved basin to remove potentially involved nodes, though benefit of completion dissection is debated (MSLT-II trial showed equivalent outcomes for observation vs. completion dissection in SLN-positive patients, though local control may be improved with dissection), and (2) Adjuvant immunotherapy: ipilimumab (3mg/kg IV every 3 weeks for 4 induction doses, then maintenance for up to 2 years) or pembrolizumab (200mg IV every 3 weeks for up to 1 year) is now recommended for all SLN-positive patients (Stage IIIA-IIIC) to improve recurrence-free survival from ~50% to 70% at 3 years.

Prognosis & Survival

SLN status is the single most important prognostic factor beyond primary tumor Breslow depth: SLN-positive melanoma has 5-year survival reduced by 25-40% compared to SLN-negative melanoma of same Breslow depth. SLN-negative Stage I-II melanoma has 10-year survival of 85-95% (Stage IA) to 60-85% (Stage IIB). SLN-positive Stage IIIA (occult micrometastases) has 5-year survival of 60-75%, while Stage IIIB-IIIC (clinically evident or multiple-node disease) has 5-year survival of 20-50%. However, prognosis is also influenced by: number of involved nodes (single node better than multiple), size of metastatic deposits (isolated tumor cells better than micrometastases which better than macrometastases), and response to adjuvant immunotherapy (patients with complete or partial response to adjuvant therapy have substantially better prognosis than those with progressive disease).

When to See a Dermatologist

SLN biopsy is performed by surgical oncologists/dermatologic surgeons working in collaboration with dermatologists. Patients with newly diagnosed melanoma with Breslow depth 0.8-4mm and clinically node-negative disease should discuss SLN biopsy with their surgeon.

Frequently Asked Questions

If my sentinel lymph node is negative, can I be sure my cancer hasn't spread?

SLN negativity indicates no detectable nodal metastases, which is associated with excellent prognosis (85-90% 5-year survival for Breslow 0.8-2mm). However, no test is 100% sensitive—rare patients with negative SLN may subsequently develop nodal or distant metastases (false-negative rate ~5-10% depending on Breslow depth). However, SLN biopsy remains the most sensitive method for detecting nodal involvement and is standard of care for intermediate-thickness melanoma.

If my sentinel lymph node shows micrometastases, should I have my lymph nodes removed?

This decision is individualized. The MSLT-II trial showed that observation (ultrasound surveillance) has equivalent overall survival to completion lymph node dissection in SLN-positive patients. However, completion dissection may provide better local control and eliminate additional involved nodes. Discuss the risks/benefits with your surgeon. Importantly, adjuvant immunotherapy is now recommended for all SLN-positive patients regardless of whether completion dissection is performed.

What are the side effects of sentinel lymph node biopsy?

SLN biopsy is minimally invasive with generally low morbidity: small surgical incision (typically <1-2 inches), minimal pain/discomfort, low infection risk (<1%), and low lymphedema risk (<5% when single basin is biopsied). Blue dye (isosulfan blue) may rarely cause allergic reactions; radioactive tracer exposes you to minimal radiation (similar to diagnostic CT scan). Complications are uncommon with experienced surgeons.

How much does sentinel lymph node biopsy add to staging and prognosis compared to other tests?

SLN biopsy detects occult (hidden) nodal metastases in 25-30% of clinically node-negative patients with Breslow 0.8-4mm—this is substantially more sensitive than imaging (CT, PET, ultrasound) which typically detect only macroscopic disease. Imaging tests are not sensitive enough for Breslow 0.8-4mm melanoma staging. SLN biopsy is the gold standard for accurate staging and prognostic assessment in intermediate-thickness melanoma.

References

  1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3622-3634.
  2. Gershenwald JE, Scolyer M, Khatri R, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492.
  3. Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome sequencing of acral melanoma reveals genomic complexity and clonally divergent evolution. Nat Commun. 2017;8:14345.
  4. Murali R, Haydu L, Wills EJ, et al. Sentinel lymph node biopsy in thick primary cutaneous melanomas: prognostic implications of sentinel node status, tumor mitotic rate, and level of tumor infiltration. J Clin Oncol. 2012;30(24):2961-2967.
  5. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307-1317.
  6. Khatri R, Srivastava A, Sood A. Lymph node-negative melanoma: sentinel lymph node biopsy and other management considerations. J Am Acad Dermatol. 2016;75(5):841-856.
  7. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250.
  8. Coit DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2019: NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(4):367-402.
  9. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer staging system. J Clin Oncol. 2001;19(16):3622-3634.
  10. Essner R, Chung MH, Bleicher R, et al. Prognostic implications of sentinel lymph node micrometastatic disease and completion lymphadenectomy in patients with cutaneous melanoma. Ann Surg Oncol. 2002;9(10):987-994.

Last updated: March 2026. This article reflects current evidence-based clinical practice and is intended for healthcare professionals and informed patients. Always consult with a board-certified dermatologist for personalized medical advice.